Strategy
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
The UK major's asthma drug gets a key expanded approval.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
The French drugmaker is expanding its neurology activities with the $470m deal.
The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.
The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.
The German biotech has been forced into insolvency and NASDAQ suspension.
Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.
The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.
The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.
A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.
The company hopes the drug will become the standard of care rescue treatment in asthma.
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.